OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 51
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 51
Showing 1-25 of 51 citing articles:
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T‐Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy
Jiajun Dong, Jinmin Miao, Yiming Miao, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 22
Open Access | Times Cited: 23
Jiajun Dong, Jinmin Miao, Yiming Miao, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 22
Open Access | Times Cited: 23
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 14
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 14
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 12
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 12
Confounding Factors in Targeted Degradation of Short-Lived Proteins
Vesna Vetma, Laura Casares Perez, J. E. Elias, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 7, pp. 1484-1494
Open Access | Times Cited: 12
Vesna Vetma, Laura Casares Perez, J. E. Elias, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 7, pp. 1484-1494
Open Access | Times Cited: 12
Structural and Physicochemical Features of Oral PROTACs
Markus Schade, James S. Scott, Thomas G. Hayhow, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13106-13116
Closed Access | Times Cited: 12
Markus Schade, James S. Scott, Thomas G. Hayhow, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13106-13116
Closed Access | Times Cited: 12
Relocalizing transcriptional kinases to activate apoptosis
Roman C. Sarott, Sai Gourisankar, Basel A. Karim, et al.
Science (2024) Vol. 386, Iss. 6717
Closed Access | Times Cited: 8
Roman C. Sarott, Sai Gourisankar, Basel A. Karim, et al.
Science (2024) Vol. 386, Iss. 6717
Closed Access | Times Cited: 8
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12559-12585
Open Access | Times Cited: 19
Zhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12559-12585
Open Access | Times Cited: 19
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Chrysanthi Kagiou, José A. Cisneros, Jakob Farnung, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Chrysanthi Kagiou, José A. Cisneros, Jakob Farnung, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy
Liuqing Yang, Ye Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Liuqing Yang, Ye Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Discovery of the First-in-Class G9a/GLP PROTAC Degrader
Julia Velez, Yulin Han, Hyerin Yim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6397-6409
Open Access | Times Cited: 6
Julia Velez, Yulin Han, Hyerin Yim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6397-6409
Open Access | Times Cited: 6
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes
Jonathan D. Taylor, Nathalie Barrett, Sergio Martínez Cuesta, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Jonathan D. Taylor, Nathalie Barrett, Sergio Martínez Cuesta, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Confounding factors in targeted degradation of short-lived proteins
Vesna Vetma, Laura Casarez-Perez, J. E. Elias, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Vesna Vetma, Laura Casarez-Perez, J. E. Elias, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Donglu Zhang, Bin Ma, Peter S. Dragovich, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 5
Donglu Zhang, Bin Ma, Peter S. Dragovich, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 5
Systematic evolution of functional oligonucleotides for targeted protein degradation
Huang Su, Yifan Chen, Xuyang Zhao, et al.
Chem (2025), pp. 102408-102408
Closed Access
Huang Su, Yifan Chen, Xuyang Zhao, et al.
Chem (2025), pp. 102408-102408
Closed Access
PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows
Robin Thomas Ulrich Haid, Andreas Reichel
Drug Discovery Today (2025), pp. 104311-104311
Open Access
Robin Thomas Ulrich Haid, Andreas Reichel
Drug Discovery Today (2025), pp. 104311-104311
Open Access
Strategies for Precise Modulation of Protein Degradation
Shipeng He, Guoqiang Dong, Chunquan Sheng
Accounts of Chemical Research (2025)
Closed Access
Shipeng He, Guoqiang Dong, Chunquan Sheng
Accounts of Chemical Research (2025)
Closed Access
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
Zhijie Deng, Jerrel L. Catlett, Youngeun Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Zhijie Deng, Jerrel L. Catlett, Youngeun Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Rational Design of Methylene Blue–Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation
Yu Zhang, Qi-Ying Yu, Ziwei Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Yu Zhang, Qi-Ying Yu, Ziwei Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Benjamin C. Whitehurst, Matthias R. Bauer, Fredrik Edfeldt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7594-7604
Closed Access | Times Cited: 11
Benjamin C. Whitehurst, Matthias R. Bauer, Fredrik Edfeldt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7594-7604
Closed Access | Times Cited: 11
A Novel Gain-of-Signal Assay to Detect Targeted Protein Degradation
Megan T. Hoffman, Keith M. Cheah, K. Dane Wittrup
ACS Synthetic Biology (2024) Vol. 13, Iss. 1, pp. 220-229
Closed Access | Times Cited: 4
Megan T. Hoffman, Keith M. Cheah, K. Dane Wittrup
ACS Synthetic Biology (2024) Vol. 13, Iss. 1, pp. 220-229
Closed Access | Times Cited: 4
Biomimetic Nano‐Degrader Based CD47‐SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair
Jinfeng Gao, Zhiqing Pang, Qiaozi Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 24
Open Access | Times Cited: 4
Jinfeng Gao, Zhiqing Pang, Qiaozi Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 24
Open Access | Times Cited: 4
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability
Hao Wu, Jeremy Murray, Noriko Ishisoko, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8585-8608
Closed Access | Times Cited: 4
Hao Wu, Jeremy Murray, Noriko Ishisoko, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8585-8608
Closed Access | Times Cited: 4
